novo nordisk glp-1 receptor agonists weight management diabetes treatments GLP-1-based therapies for diabetes, obesity and beyond Novo Nordisk to launch Ozempic

Evidence has recently revealed that GLP-1RAs inhibit cardiac hypertrophy by upregulating GLP-1R expression and activating the AMPK/mechanistic target of the rapamycin (mTOR) signaling pathway [78]

Whilst there is also evidence that sulforaphane reduces cancer development, future research on the underlying molecular mechanisms is also warranted to further understand the role of sulforaphane in the metabolic rewiring of cancer progression

Hollow magnetic nanocarrier-based microrobot swarms for NIR-responsive targeted drug delivery and synergistic therapy

Botox is a purified protein that temporarily relaxes targeted muscles

BPC-157 is a synthetic pentadecapeptide derived from human gastric BPC protein

Frequently Asked Questions About Self-Administering Injections 1